People: Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,799.00GBp
11:35am EDT
Price Change (% chg)

-12.00p (-0.66%)
Prev Close
1,811.00p
Open
1,820.00p
Day's High
1,820.00p
Day's Low
1,791.00p
Volume
183,555
Avg. Vol
237,127
52-wk High
1,835.00p
52-wk Low
1,000.61p

Search Stocks

Summary

Name Age Since Current Position

Said Darwazah

56 2014 Chairman of the Board, Chief Executive

Mazen Darwazah

56 2014 Executive Vice Chairman of the Board; President and Chief Executive Officer of MENA and Emerging Markets

Khalid Nabilsi

2011 Chief Financial Officer

Michael Raya

2008 President and Chief Executive Officer, USA

Ibrahim Jalal

2008 Senior Corporate Vice President - Technical Affairs

Majda Labadi

2009 Corporate Vice President - Human Resources

Susan Ringdal

2012 Vice President - Corporate Strategy and Investor Relations

Riad Mishlawi

2011 EU Vice President and Global Head - Injectables

Fadi Nassar

2007 Corporate Vice President - Active Pharmaceutical Ingredients

Ragheb Al-Shakhshir

2009 Corporate Vice President - Research & Development

Hussein Arkhagha

2013 General Counsel

Bassam Kanaan

48 2014 Chief Strategy & Corporate Development Officer

Peter Speirs

2012 Company Secretary

Ali Al-Husry

56 2005 Non-Executive Director

Michael Ashton

68 2005 Non-Executive Independent Director

Patrick Butler

53 2014 Non-Executive Independent Director

Breffni Byrne

68 2005 Non-Executive Independent Director

Ronald Goode

70 2006 Non-Executive Independent Director

Robert Pickering

54 2014 Senior Non-Executive Independent Director

Biographies

Name Description

Said Darwazah

Mr. Said Darwazah is has been appointed as Chairman of the Board, Chief Executive Officer of Hikma Pharmaceuticals Plc., effective May 15, 2014. Said was appointed Chief Executive Officer in July 2007. Said was Chairman and Chief Executive of Hikma’s group holding company from 1994 to 2003 and Minister of Health for the Hashemite Kingdom of Jordan from 2003 to 2006. During his 32 years at Hikma, Said has undertaken several executive roles which have provided him with extensive experience in each functional area of Hikma’s global generic pharmaceuticals business and in the broader strategic leadership of an international entrepreneurial organisation. Said has played a key role in the development of the Group strategy, including the acquisition of West-Ward Pharmaceuticals in the US and the development of the Injectables business in Europe and the MENA region. Under Said’s leadership, Hikma’s facilities in the US , Jordan and Portugal received US FDA approval, the leading international pharmaceutical regulatory standard. Said has a degree in industrial engineering from Purdue University and an MBA from INSEAD. Said holds various public and charitable positions. He is founder of the Healthcare Accreditation Council of Jordan, Chairman of the Dead Sea Touristic and Real Estate Investments and a member of the Central Bank of Jordan Board. He is a Director of Endeavour Jordan, a charitable organisation that assists in the development of entrepreneurs, and a Trustee of Jordan River Foundation, a charitable organisation that aims to empower Jordanian society. Said is Chairman of the Queen of Jordan’s charitable foundation. Said is a Trustee at the American University of Beirut.

Mazen Darwazah

Mr. Mazen Samih Talib Darwazah is Executive Vice Chairman of the Board; President and Chief Executive Officer of MENA and Emerging Markets of Hikma Pharmaceuticals Plc. Mazen was appointed Group Executive Vice Chairman and MENA CEO in 2005 and became President and CEO of MENA and Emerging Markets in 2014. During his 28 years’ service at Hikma, he has held an extensive range of positions within the Group starting as a medical representative and working in different capacities including Chairman and CEO of Hikma Pharmaceuticals Limited, a major group operational and holding company. Mazen is responsible for the strategic direction of the MENA business, as well as having day-to-day operational responsibility. He is also responsible for the expansion of the Group into emerging markets outside of the MENA region, global alliances, business relationships, CSR and business integrity. Mazen holds a BA in Business Administration from the Lebanese American University and an AM P from INSEA D. He has served as the President of the Jordanian Association of Manufacturers of Pharmaceuticals and Medical Appliances. Mazen holds various public and charitable positions. Mazen is a Senator of the Hashemite Kingdom of Jordan and the Chairman of the Jordan International Insurance Company. He is Vice Chairman of the Capital Bank of Jordan. Mazen is also a Member of Board of Trustees of Yarmouk University (Jordan). He is on the advisory board for the Lebanese American University (LAU ) Lebanon, and the Buck Institute for Education, San Francisco.

Khalid Nabilsi

Mr. Khalid Nabilsi is Chief Financial Officer of Hikma Pharmaceuticals Plc., since 2011. Prior to assuming his current role, Khalid held several senior positions in the Hikma finance department including Corporate Vice President, Finance and was a key member of the IPO team in 2005. Following qualification as a CPA he held a variety of roles in financial accounting, reporting and financial advisory services, and with Atlas Investment Group (now AB Invest) where he was involved in mergers and acquisitions advisory services. Prior to Atlas, Khalid had managed several multinational audit engagements at Arthur Andersen in Amman, Jordan. As Chief Financial Officer, Khalid has integrated several acquisitions into the financial reporting structure, developed the Group internal control framework and implemented new leverage arrangements to fund acquisitions and capital investment. Khalid is a US Certified Public Accountant and has an MBA from the University of Hull. Khalid is a founder of the Jordan Association for Management Accountants and a Board member of the Jordan Armed Forces and Security Apparatuses Credit Union.

Michael Raya

Mr. Michael Raya is President and Chief Executive Officer, USA of Hikma Pharmaceuticals Plc. Michael joined Hikma’s US subsidiary West-Ward from Vitarine Pharmaceuticals where he had worked from 1984 until 1992 in various roles, including Vice President, Quality Control. Prior to this, Michael worked at Schering-Plough and Hoffman LaRoche. At Hikma, Michael has previously been responsible for all West-Ward’s operations as well as quality/compliance for all worldwide Hikma facilities until his appointment as President and CEO of West-Ward in 2008. Michael holds a Masters degree in Industrial Pharmacy from Long Island University and a Bachelor’s degree in Chemistry from St. Francis College. Michael is also a graduate of INSEA D’s International Executive Program.

Ibrahim Jalal

Dr. Ibrahim Jalal is Senior Corporate Vice President - Technical Affairs of Hikma Pharmaceuticals Plc. Ibrahim joined Hikma as Technical Director and has held a variety of roles including Corporate Technical Vice President for Compliance and Senior Corporate Vice President for RandD. He has played a leading role in Hikma securing FDA approval for its manufacturing units. Ibrahim holds a PhD in Pharmacy from the University of Wisconsin-Madison.

Majda Labadi

Ms. Majda Labadi is Corporate Vice President - Human Resources of Hikma Pharmaceuticals Plc. During her 28 years at Hikma, Majda has held a variety of roles including Purchasing Manager at Hikma Pharmaceuticals Limited, Strategy Manager at Hikma Investment, General Manager of Hikma Farmaceutica and Vice President of Injectables. In February 2009 Majda assumed her current position as Corporate Vice President, Human Resources. She has been responsible for establishing a central human resource practice and leading the development of several Group-wide initiatives, including the grading structure, performance evaluation process and the Group bonus scheme. Majda has completed the Advanced Management Program (AM P) programme at INSEA D, holds a BA from the American University of Beirut and Masters degree from Hochschule Fur Okonomie in Berlin, Germany.

Susan Ringdal

Ms. Susan Ringdal is Vice President - Corporate Strategy and Investor Relations of Hikma Pharmaceuticals Plc. Susan joined Hikma as Investor Relations Director, having previously worked for the pharmaceutical distribution and retail pharmacy group Alliance UniChem plc as Investor Relations Manager. She also has experience as an equity analyst at Morgan Stanley in London. In early 2012 Susan assumed responsibility for corporate strategy. Susan holds a BA in History from Cornell University and an MBA from London Business School.

Riad Mishlawi

Mr. Riad Mishlawi is EU Vice President and Global Head - Injectables of Hikma Pharmaceuticals PLC. Riad joined Hikma as a Project Engineer in the engineering department where he was involved in the construction of Hikma’s facility in Portugal. Riad spent a significant period in the manufacturing operations of many Hikma sites, was general manager of Hikma Italy and became Head of Injectables Manufacturing Operations before assuming his current role. Riad was an Executive Director at Watson Pharmaceuticals from 1998 to 2005, responsible for Injectables operations. Riad has led the Injectables division through a period of rapid growth and has integrated operations into a global operation. Riad has a BSc in Engineering and a Masters in Engineering and Management from George Washington University.

Fadi Nassar

Mr. Fadi Nassar is Corporate Vice President - Active Pharmaceutical Ingredients of Hikma Pharmaceuticals Plc. Fadi has worked in various roles within the Group including Operations, Purchasing and Business Development. He was promoted to Corporate Vice President, API in 2007. Fadi is a Director of Hubei Haosun Pharmaceutical Co. Ltd., an Active Pharmaceutical Ingredient manufacturing company in which Hikma purchased a significant minority interest in 2011. Fadi holds a BSc in Chemical Engineering from Newcastle University and an MS c in Chemical Engineering from Leeds University. Fadi is also a graduate of INSEA D’s International Executive Program.

Ragheb Al-Shakhshir

Mr. Ragheb Al-Shakhshir is Corporate Vice President - Research & Development of Hikma Pharmaceuticals Plc. Ragheb joined Hikma as a Research and Development Manager. Prior to joining Hikma he held a variety of roles as Senior Scientist at Novartis Pharmaceuticals, and at Alcon Labs in the US . From 2003–2008 Ragheb led the Hikma R&D Injectables team and from February 2009 assumed the responsibility of Corporate Vice President, Research and Development. Ragheb has a PhD in Industrial and Physical Pharmacy from Purdue University, Masters in Engineering from the University of Massachusetts- Amherst and a BSc in Chemical Engineering from the University of Wisconsin-Madison.

Hussein Arkhagha

Mr. Hussein Arkhagha is General Counsel of Hikma Pharmaceuticals PLC. Hussein joined Hikma in July, 2001 as a Legal Counsel. Since then, Hussein occupied several positions at Hikma, including Head of Tax, Head of MENA Legal and Head of Shareholders Department. Hussein is a qualified lawyer in Jordan and holds a Masters degree in International Business Law from the University of Manchester, under UK Chevening Scholarship.

Bassam Kanaan

Mr. Bassam Wael Rushdi Kanaan is Chief Strategy & Corporate Development Officer of Hikma Pharmaceuticals Plc. Bassam started his career in 1986 with Deloitte & Touche (Los Angeles) where he held a variety of roles prior to joining PADICO in 1994 as CFO. Bassam joined Hikma as CFO in 2001 and played a leading role in preparing for Hikma’s IPO in 2005 and in its subsequent M&A activity. In February 2009, in addition to his responsibilities as CFO, Bassam assumed responsibility for Operations, Manufacturing and Supply Chain management in Europe & MENA . In January 2011, Bassam was promoted to the position of President and Chief Operating Officer for the MENA and EU regions, where he led the implementation of important organisational and operational improvements. In 2014 he was promoted to the newly created role of Chief Strategy & Corporate Development Officer, with Group-level responsibility for strategic development, acquisitions, alliances and product development. Bassam is responsible for delivering the expansion vision of the CEO . Bassam is qualified as a Certified Public Accountant (CPA) and Chartered Financial Analyst (CFA). Bassam has a BA from Claremont McKenna College and an International Executive MBA from Kellogg/Recanati Schools of Management. Bassam currently holds a Non-Executive Directorship in Arab Bank. He has previously served on the Boards of Aqaba Development Co., Jordan Dubai Properties, Zara Holding, Capital Bank of Jordan, CE GCO and Paltel. Bassam is active in several non-profit and charity organisations and is currently a member of the Board of Trustees of the Welfare.

Peter Speirs

Mr. Peter Speirs is Company Secretary of Hikma Pharmaceuticals PLC. Peter joined Hikma as a Deputy Company Secretary in 2010. Prior to joining Hikma, he worked in the Corporate Secretariat of Barclays and Pool Re, the UK terrorism re-insurer. He also worked at Manifest, a leading Corporate Governance Agency. In 2012, Peter assumed the role of Company Secretary. Peter is responsible for advising on governance and listing matters at the Board and across the Group and ensuring the smooth management of the Board and committees. Peter is a Fellow of the Institute of Chartered Secretaries and Administrators and holds a Law degree from University of East Anglia.

Ali Al-Husry

Mr. Ali K. Al-Husry is Non-Executive Director of Hikma Pharmaceuticals Plc. Ali joined Hikma as Director of Hikma Pharma Limited in 1981 and has held various directorships within the Group. Ali brings great financial experience to the Board as well as an in-depth knowledge of the MENA region and Hikma Pharmaceuticals. Ali was a founder of The Capital Bank of Jordan, which offers commercial and investment banking services, and served as Chief Executive Officer of the Bank until 2007. Ali has a degree in Mechanical Engineering from the University of Southern California and an MBA from INSEAD. Ali is Chairman of Endeavour Jordan, a not for profit organisation that assists in the development of entrepreneurs and a Director of the Microfund for Women, which provides microfinance to low-income female entrepreneurs. Also, he is a director of the Capital Bank of Jordan.

Michael Ashton

Mr. Michael Richard Dwyer Ashton is Non-Executive Independent Director of Hikma Pharmaceuticals Plc. Michael has over 30 years’ experience in the pharmaceutical industry, holding senior executive positions with Pfizer and Merck. Michael was Chief Executive Officer of SkyePharma PLC from November 1998 to March 2006 and prior to that was Chairman, President and Chief Executive Officer of Faulding. He has held a number of non-executive and advisory positions across the pharmaceutical industry. Michael has a Bachelor of Pharmacy degree from Sydney University, and his MBA degree from Rutgers University, New Jersey. Michael is a Non-Executive Director at Transition Therapeutics, a therapeutics biopharmaceutical company. He is also Chairman of PuriCore plc, water-based clean technology company, and Komix, a children’s educational organisation.

Patrick Butler

Mr. Patrick Butler is Non-Executive Independent Director of the Company since April 1, 2014. Pat is a former Senior Director at Mckinsey & Co. During his 25 years at McKinsey, he focused on advising large corporations in the EU, US and MENA on strategic, acquisition, and organisational issues. He has extensive experience in strategy implementation, integrating acquisitions, performance improvement and a range of finance functions including treasury and risk management. Prior to McKinsey, Pat qualified as a Chartered Accountant with the audit and tax practice of Arthur Andersen. He has a first class honours degree in Commerce and a postgraduate diploma in Accounting and Corporate Finance from University College Dublin. Pat has a first class honours degree in Commerce and a postgraduate diploma in Accounting and Corporate Finance from University College Dublin. Pat is a partner at The Resolution Group, Non-Executive Director of the Bank of Ireland and governor of the British Film Institute. He also chairs the Investment Committee of the UK government’s Business Bank.

Breffni Byrne

Mr. Breffni Byrne is Non-Executive Independent Director of Hikma Pharmaceuticals Plc. Breffni is a chartered accountant with over 30 years of experience in public practice, including significant international responsibilities. Breffni served as the Managing Partner of the Audit and Business Advisory practice of Arthur Andersen in Ireland and as Director of Risk Management of Andersen’s audit practice in Middle East, India, Africa and the Nordic countries. Breffni has extensive experience in financial reporting, international operations, corporate governance and general financial and commercial matters. He is a former Non-Executive Director of Irish Life and Permanent plc. He is considered by the Board to have recent and relevant financial experience. Breffni holds a Masters degree in Economic Science from the University College, Dublin and is a Chartered Accountant. Breffni is Chairman of Aviva’s life insurance operations in Ireland and Tedcastles Holdings, an oil distribution company. He is also a Non-Executive Director of Citibank Europe PLC and Cpl Resources plc, a human resources company. He has been a member of the Audit Committee of all of the above companies, in some cases Chairman.

Ronald Goode

Mr. Ronald L. Goode is Non-Executive Independent Director of Hikma Pharmaceuticals Plc. Ron has spent over 30 years in the international pharmaceutical industry, including roles as President of International Operations at Searle and Vice President of Clinical and Scientific Affairs at Pfizer. His extensive experience includes leading companies as CEO and acting as an adviser to companies in the pharmaceutical industry. He also advises companies involved in nanotechnology and in the information technology business sectors. Ron was formerly President and Chief Executive Officer of Unimed Pharmaceuticals, Inc. and eXegenics Inc. He is a trustee of Thunderbird School of Global Management, which is ranked by the Financial Times as the premier international business school. Ron has a PhD from the University of Georgia and a MS and BS from the University of Memphis. Ron is the Chairman of The Goode Group, advisers to the pharmaceutical industry. Ron is a Director of Mercy Ships International, a medical services charity. He is a Senior Business Advisor to The Kinsella Group, an investment banking company.

Robert Pickering

Mr. Robert M. Pickering has been appointed as Senior Non-Executive Independent Director of Hikma Pharmaceuticals PLC., effective May 15, 2014. Robert spent 23 years at Cazenove and Co., becoming the first Chief Executive of Cazenove Group PLC in 2001. He subsequently served as Chief Executive of JP Morgan Cazenove, until his retirement in 2008. He has extensive experience of capital raising, mergers and acquisitions and of the relationship between quoted companies and investors. Robert is a qualified solicitor with a law degree from Lincoln College, Oxford. Robert is a Non-Executive Director of Neptune Investment Management, a fund management company and Itau BBA International PLC , the investment bank of the Itaú Unibanco group. He is Chairman of the Trustees of Lincoln College Oxford 2027 Trust.
Search Stocks